INS and cancer: In renal failure often highly insulin sensitiveIn liver failure/cirrhosis often insulin resistant with predominant need for meal‐time insulinIn cancer and many other terminal conditions insulin doses may fall away with terminal cachexia/loss of appetite; higher glucose control targets are acceptable with short‐life expectancy31